The Food and Drug Administration set a new review date of March 1 for Exalgo.

The U.S. rights to Exalgo tablets were acquired from Neuromed by Mallinckrodt Inc., a Covidien company, in June, 2009.

Neuromed then acquired the U.S. marketing rights to Exalgo tablets from ALZA Corporation in April 2007 and was responsible for clinical development and regulatory filings. CombinatoRx and Neuromed merged on December 21, 2009.

Covidien, which is based in Ireland and whose U.S. headquarters are in St. Louis, is responsible for all commercialization activities for Exalgo in the U.S., including marketing, sales and all post-approval FDA regulatory filings, and will now own the intellectual property for the product. ALZA is responsible for manufacturing, packaging and supply of the product.

The drug is an extended-release opioid painkiller. It will be interesting to see how shares react to the news which was released one minute after the market closed on Tuesday.  Most investors react negatively to delay news, but the announced delay is only one week.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites